We determined the alleles of 11 mHAs and investigated the association of immunogenic mHA mismatches between a donor and a recipient with a course of allogeneic hematopoietic SCT (allo-HSCT) from 10/10 alleles HLA-matched unrelated donors in 92 recipients after myeloablative conditioning between 2004 and 2006. The frequency analysis of mHA alleles, genotypes and phenotypes accompanied by appropriate restriction HLA Ags allowed for an estimation of the probability of immunogenic mismatches, which was the highest for HA-1, HA-8 and HY. GVH-directed disparity of mHAs with broad tissue distribution, especially of the sex-related HY Ag, influenced the results of allo-HSCT from HLAmatched unrelated donors by not only increasing the probability of chronic GVHD (cGVHD) but also by decreasing the relapse rate.
Introduction
The complicated or favorable course of HLA-matched allogeneic hematopoietic SCT (allo-HSCT) has been attributed to genetic differences exceeding the HLA system, leading to immunologic interactions between a donor and a recipient. [1] [2] [3] [4] [5] The mHAs are immunogenetic factors that may affect the results of allogeneic transplants. We have searched for immunogenic disparities of mHAs in unrelated HLA-matched donor/recipient pairs and for their associations with survival and transplant complications such as GVHD, graft failure (GF) and relapse.
Materials and methods
Eleven mHAs were analyzed in the group of 92 patients treated with 10/10 HLA A, B, C, DR and DQ allele-matched unrelated allo-HSCT from January 2004 to December 2006. HLA was typed with the use of the allele-specific PCRsequence specific primers (SSP) method. The detailed characteristics of donor/recipient pairs, transplant procedures and complications are shown in Table 1 . Antithymocytic globulin, either Thymoglobulin (Genzyme, Cambridge, MA, USA) 6 mg/kg or ATG (Fresenius, Bad Homburg, Germany) 30 mg/kg, was given before allo-HSCT. BM or G-CSFstimulated peripheral blood was the source of stem cells, dependent on ABO compatibility or a donor's preferences. GVHD prophylaxis consisted of CsA starting on day À1 at dose 3 mg/kg i.v., further adjusted according to serum CsA concentration, and MTX 15 mg/m 2 on day þ 1, 10 mg/m 2 on days þ 3 and þ 6 and, optionally, þ 10. All allo-HSCT procedures and DNA isolations were performed in the Department of Hematology and Bone Marrow Transplantation, Medical University of Silesia in Katowice, Poland. mHA genotyping was performed in the Immunogenetics and HLA Laboratory of Regional Blood Center in Katowice, Poland. A study protocol was accepted by a local bioethic committee. Recruitment of patients was preceded by their informed consent. mHAs typing DNA was isolated from the BM or peripheral blood samples collected from donors and recipients before allo-HSCT. The allele-specific PCR-SSP method with Dynal AllSet þ Minor Histocompatibility Antigen Typing Kit (Invitrogen, Carlsbad, CA, USA) allowed for genotyping of 11 mHAs as follows: HA-1, HA-2, HA-3, HA-8, HB-1, ACC-1, ACC-2, HwA-9(SP110), HwA-10(PANE1), UGT2B17 and HY. Typing was performed according to published recommendations. 6 PCR-SSP products were analyzed on agarose gel and each identified mHA allele was coded as an amino acid produced by a single nucleotide polymorphism.
Most mHAs display a unidirectional recognition pattern with one immunogenic allele and another nonimmunogenic allele. For example, HA-1 may be encoded by immunogenic H and nonimmunogenic R alleles, and thus possible genotypes include the heterozygotic genotype HR and homozygotic genotypes HH and RR. Homozygous individuals with both immunogenic alleles (HH) and heterozygous individuals with one immunogenic allele and another nonimmunogenic allele (HR) are assumed to possess immunogenic phenotypes, whereas homozygous individuals with both nonimmunogenic alleles (RR) are assumed to possess nonimmunogenic phenotypes. Immunogenic disparity was identified when, within a given donor/recipient pair, only one individual had an immunogenic phenotype of a particular mHA accompanied by the appropriate HLA restriction molecule. Nonimmunogenic disparity was identified when mHA genotypes in a donor and a recipient were different, but phenotypically they were either the same or the immunogenic mHA phenotype was not accompanied by the appropriate HLA restriction molecule. Only immunogenic mHA disparities were included in the analysis.
Immunogenic mHA disparity may be directed either in GVH direction (immunogenic recipient and nonimmunogenic donor), or in host-vs-graft (HVG) direction (nonimmunogenic recipient and immunogenic donor). The information on whether mHA mismatches accompanied by relevant HLA molecules might result in GVH or HVG responses was established with the use of the minor Histocompatibility Knowledge Database of Leiden University Medical Center (http://www.lumc.nl/dbminor). The pattern of mHA tissue distribution (restricted or broad) was also established according to the database.
Statistical analysis
The probability of disease-free survival (DFS) was estimated by the Kaplan-Meier method and shown as percentage ± 95% confidence interval (CI). 7 The interval from allo-HSCT to relapse or death, whichever occurred first, was a complete (finished) observation, and to the last visit in remission was a censored observation in DFS analysis. 8 Acute GVHD (aGVHD) was evaluated in patients alive at day þ 21 with engraftment, chronic GVHD (cGVHD) was evaluated in patients alive at day þ 100 and relapse was evaluated in patients with malignant disease. The probability of aGVHD, cGVHD and relapse was calculated as cumulative incidence and shown as percentage ± 95% CI in accordance with European Group for Blood and Marrow Transplantation recommendations. 9, 10 Competing risks were relapse or death without preceding aGVHD or cGVHD in GVHD analysis, and death in remission in the relapse analysis. The prognostic value was estimated by comparison of two survival curves in log-rank test. The risk of events in particular groups was estimated by odds ratio and 95% CI in a logistic regression model. The mHA effect on GF and the presence of GVHD on day þ 100 were shown as a direct proportion, and matched and mismatched groups were compared by Fisher's exact test.
The influence of clinical factors (variables included patient age, diagnosis, disease status at allo-HSCT, a preparative regimen, cell source, donor's sex and sex compatibility) on study end points was evaluated in univariate (w 2 -test and Fisher's exact test) and multivariate analyses performed with logistic regression.
GF was diagnosed when granulocyte count was less than 0.5 Â 10 9 /l 28 days after allo-HSCT. A P-value of less than 0.05 was regarded as statistically significant. Statistical analyses were performed using the professional statistical program STATISTICA, version 6.0.
Results
The frequency of mHA alleles and mHA phenotype disparities The frequency of mHA alleles, genotypes and phenotypes is presented in Table 2 . One to six mHA immunogenic disparities were revealed in 73 pairs: in 49 GVH-and in 50 HVG-directed (data not shown). Table 2 Allele, genotype and phenotype frequencies of 11 mHAs in 92 donor/recipient pairs The chance for a different phenotype in a donor and a recipient was higher when the frequency of immunogenic and nonimmunogenic phenotypes was balanced, as it was observed for HY and autosomal mHAs HA-1 and HA-8, and when the frequency of relevant restriction molecules presented in Table 3 was high. The frequency of HLA-A*02 restrictive for HY, HA-1 and HA-8 was higher than the frequencies of HLA molecules restrictive for other autosomal mHAs. Many other HLA Ags may also serve as restriction molecules for HY, including frequent HLA-A*01, DRB1*1501 and DQB1*05, which contributed to an even higher chance of immunogenic HY mismatch.
Disease-free survival A trend toward better DFS was observed when HY was mismatched in GVH direction. DFS was influenced by the cell source and donor's sex (Table 4 ). Better DFS was observed when peripheral blood was the cell source and after transplants from female donors.
Overall survival
The mHA disparities did not influence overall survival. Overall survival was influenced by a preparative regimen and by the cell source ( Table 4 ). The best survival was observed after preparation with treosulfan and fludarabine and when peripheral blood was the cell source.
GVHD
Unexpectedly, mHA disparities in GVH direction did not influence the presence, duration or clinical stage of aGVHD (data not shown). In contrast, clinically significant aGVHD (II-IV) was more frequent when HVG-directed mHA disparities of HA-3 (67% (95% CI: 29-100%) vs 22% (95% CI: 13-21%), P ¼ 0.03) and HY (43% (95% CI: 22-64%) vs 20% (95% CI: 11-29%), P ¼ 0.04) were present in six and 22 patients, respectively. Both HA-3 and HY present broad tissue distribution. The occurrence of aGVHD was influenced by donor's sex (Table 4) : more frequent aGVHD was observed after allo-HSCT from male donors.
The incidence of cGVHD was significantly increased by HY disparity in GVH direction (66 vs 38%, P ¼ 0.02) ( Figure 1 and Table 5 ). The more frequent occurrence of cGVHD was observed after transplantation from female donors, and other clinical factors did not influence cGVHD (Table 4) . When both factors were analyzed separately in w 2 -test, cGVHD was independently influenced by GVHdirected HY disparity (P ¼ 0.04) and by donor's sex (P ¼ 0.04). No simultaneous effect of donor's sex and GVH-directed HY disparity on cGVHD was shown in logistic regression analysis. Pooled disparities of mHAs with broad tissue distribution increased cGVHD incidence less significantly. A similar effect of mHA disparities was observed with regard to the presence of GVHD examined on day þ 100. The analysis of influence of HVG-directed mHA disparities on cGVHD revealed a tendency of lower cGVHD incidence in eight patients with mismatched HA-1 (13% (95% CI: 0-39%) vs 44% (95% CI: 32-56%), P ¼ 0.09).
Graft failure
A trend toward more frequent occurrence of GF was observed in eight and four patients with HVG-directed (Table 5) . Clinical factors did not influence GF (Table 4) .
Relapse
Analysis of mHAs revealed significantly lower relapse rate in 17 patients with HY GVH-directed disparities (6 vs 23%, P ¼ 0.046) ( Figure 2 and Table 5 ). Simultaneous effect of donor's sex and GVH-directed HY disparity on cGVHD was shown in log-linear analysis. No influence of HVGdirected mHA mismatches on relapse rate was observed. A higher relapse rate was observed when allo-HSCT was performed not in the first CR, when cell source was the BM, after allo-HSCT from male donors and after sexincompatible allo-HSCT from male donors to female recipients (Table 4) .
Discussion
There is a growing evidence indicating that mHAs may be important in allo-immunological interactions after allo-HSCT. Introducing a modern method of molecular identification of 11 mHAs 6 opened the possibility to study the role of their disparities in donor/recipient pairs in allogeneic transplants. Obviously, many of the immunogenic disparities restricted to specific HLA alleles do occur at a low frequency, and therefore the current study is underpowered to detect any difference for many of the mHAs. Although all pairs in this study were 10/10 HLA alleles (A, B, C, DR and DQ) matched, DP typing was not performed, and thus the potential influence of DP incompatibilities on outcomes was not excluded.
The assessment of mHA phenotype frequencies and disparities is important for the identification of mHAs, which could be used for possible immunotherapeutic applications, including mHA vaccination.
12,13 mHAs with tissue distribution restricted to the hematopoietic system matter in the GVL effect after allo-HSCT.
14 Broadly expressed mHAs are prone to causing GVHD. 6 Prospective genomic typing for the mHA alleles of donor and recipient No HY GVH-directed mismatch, n=70 Figure 1 Influence of GVH-directed disparity of HY on cGVHD.
Disparities of mHAs in allo-HSCT M Markiewicz et al should improve donor selection in case several 10/10 alleles HLA-matched donors are available and should allow the determination of recipients with high risk for mHAinduced GVHD development.
Presence of mHA disparities
The mHA frequency studies are restricted to reports on a few mHAs in Caucasians 15 and a recent report on 10 autosomal mHA distributions studied worldwide.
11 Some additional genotype data of selected mHAs were acquired, thanks to the HapMap project. 16 In the Polish population, only HA-1 alleles have been studied in a group of 30 related donor/recipient pairs 17 until now. We have evaluated the frequency of genotypes and phenotypes of 11 mHAs and the occurrence of their restriction HLA molecules to identify those immunogenically mismatched mHAs that possess relatively frequent restriction HLA molecules, and thus may serve as candidates for a potential immunotherapeutic use. This study revealed similar differences in the presence of HA-1 genotypes as reported earlier: the most frequent was the heterozygotic genotype HR (47-48%); less frequent was the homozygotic genotype RR (41-42%) and the least frequent was the homozygotic genotype HH (10-12%). In consequence, the frequency of immunogenic (HH and HR) and nonimmunogenic (RR) phenotypes was uniform in our population, which led to a relatively high probability of their immunogenic disparity in donor/ recipient pairs. A similar distribution of immunogenic and nonimmunogenic phenotypes was observed in the case of HA-8 (RR and RP vs PP) and HY ( þ vs À). Autosomally coded HA-1, HA-8 and sex-related HY are mHAs present on hematopoietic cells and they may be used for immunotherapeutic purposes (induction of GVL effect and so on).
mHA disparities and GVHD Observations of allo-HSCT with sex differences indicate the possibility that mHAs with broad tissue distribution may be responsible for the more frequent occurrence of GVHD. 18, 19 Our results indicate that GVH-directed immunogenic disparities of mHAs with broad tissue distribution, especially of sex-related Ag HY, influence the occurrence of cGVHD, confirming our earlier observation 20 and other reports. 21, 22 The presence of GVHD examined on day þ 100 was also associated with HY GVH disparity. The influence on cGVHD was not dependent on the number of GVH-directed mHA disparities (1-5 disparities of such type were observed). A similar effect on GVHD was also reported earlier for mHAs present solely on hematopoietic cells, such as HA-1, 4, [23] [24] [25] [26] HA-2 23 and HA-8, 27 although it was not confirmed by others. [28] [29] [30] [31] We have observed only a trend toward more frequent cGVHD in the presence of GVH-directed immunogenic disparities of mHAs with restricted tissue distribution. Moreover, when HA-1 mismatch was directed oppositely (in HVG direction), cGVHD tended to occur less frequently. Table 5 Analysis of transplant outcome in patients with and without mHA disparity at risk of an event No HY GVH-directed mismatch, n=76 Cumulative incidence Days after transplantation Figure 2 Influence of GVH-directed disparity of HY on relapse rate.
Disparities of mHAs in allo-HSCT M Markiewicz et al
We have not found an association between GVHdirected mHA disparities and occurrence and clinical stage of aGVHD. A correlation between HVG-directed disparities HA-3 and HY (both are mHAs with broad tissue distribution) and aGVHD was unexpectedly revealed, and it needs further confirmation. If confirmed, it might suggest that surviving immunocompetent recipient cells may react to mismatched mHAs broadly expressed on donor cells. Such an inter-reaction may initiate 'defense' of donor cells with possible engagement of inflammatory reaction mechanisms leading to GVHD. An inflammatory reaction, as well as a cytokine storm leading to tissue damage and an initiation of GVHD without a reaction between donor lymphocytes and mHAs present in the recipient tissue affected by GVHD, was shown by others. [32] [33] [34] mHA disparity and graft failure Preclinical study of Laylor 35 evidenced that GF after allo-HSCT may be a consequence of HVG reaction initiated by mismatch of a single mHA recognized by T lymphocytes as a 'foreign' Ag. Clinical observations of GF after allo-HSCT with reduced conditioning and T depletion are consistent with this finding. 36, 37 Studies of the Leiden group proved that lymphocytes of a host who fails to engraft may be directed against both autosomal and sex-related donor's mHAs. 38, 39 Moreover, an increased rate of GF and poorer survival observed in female recipients transplanted from male donors may be attributed to the disparities of Y chromosome-related mHAs. [40] [41] [42] We have found a similar tendency of more frequent GF in the group of patients with HVG-directed mHA disparities of autosomal Ags HA-1 and HA-2. Both immunogenic Ags were present solely on the donor's hematopoietic cells in this group of patients. mHA disparity and relapse Autosomal mHAs such as HA-1, HA-2, HA-3, HA-8, HB-1 and all sex-related mHAs present on leukemic cells may serve as a target for donor T lymphocytes responsible for GVL reaction, and thus may decrease the relapse rate in case of mHA mismatch. [43] [44] [45] We have observed the favorable effect of GVH-directed mismatch of sex-related mHA HY on the relapse rate, which is in concordance with earlier reports. 21, 46 It can be noted that a favorable relapse rate was observed in the kind of mismatch that requires female donors, which denies the opinion that female donors do worse. A Japanese study 47 has shown the positive role of GVH-directed HA-1 mismatch on the relapse rate. In that study, however, not only the patients with restrictive HLA-A*02 molecules, but also those with other HLA class I superfamilies were included in the analysis. We have analyzed only mismatched pairs possessing restriction HLA Ags and have not observed the favorable role of GVH-directed HA-1 mismatch on the relapse rate.
